These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1306 related items for PubMed ID: 27001083

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y, Ma Y, Li Y, Shen X, Yu Y, Pan Y, Zhang Y, Yu S, Zheng D, Zhao Y, Hu H, Sun Y, Zhang Y, Xiang J, Chen H.
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
    Sakashita S, Shiba-Ishii A, Murata Y, Sekimoto R, Minami Y, Sato Y, Noguchi M.
    Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
    [Abstract] [Full Text] [Related]

  • 8. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
    Zhou J, Ben S.
    Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
    Ono A, Kenmotsu H, Watanabe M, Serizawa M, Mori K, Imai H, Taira T, Naito T, Murakami H, Nakajima T, Ohde Y, Endo M, Yamamoto N, Koh Y, Takahashi T.
    Ann Oncol; 2014 Oct; 25(10):1948-1953. PubMed ID: 25009007
    [Abstract] [Full Text] [Related]

  • 13. Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.
    Liang S, Wang H, Zhang Y, Tian H, Li C, Hua D.
    Cancer Med; 2024 Apr; 13(8):e7208. PubMed ID: 38659399
    [Abstract] [Full Text] [Related]

  • 14. The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
    Sárosi V, Balikó Z, Smuk G, László T, Szabó M, Ruzsics I, Mezősi E.
    Pathol Oncol Res; 2016 Oct; 22(4):755-61. PubMed ID: 27105879
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
    Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, Chen JJW, Chen HW, Yu SL, Yang TY, Chang GC.
    Cancer Res Treat; 2018 Oct; 50(4):1294-1303. PubMed ID: 29334606
    [Abstract] [Full Text] [Related]

  • 18. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS.
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.